ライフサイエンスコーパス: methotrexate

1 and methotrexate; and 386 had adalimumab and methotrexate).

2 or in combination with either ciclosporin or methotrexate.

3 favoured the combination of prednisone plus methotrexate.

4 the MAP group: bone marrow infarction due to methotrexate.

5 ients with a previous inadequate response to methotrexate.

6 rDHFR-1 exhibited similar affinities towards methotrexate.

7 and not to original treatment with high-dose methotrexate.

8 eceived GVHD prophylaxis with tacrolimus and methotrexate.

9 dnisone plus ciclosporin and prednisone plus methotrexate.

10 prophylaxis was composed of cyclosporine and methotrexate.

11 orin, and 46 were randomised prednisone plus methotrexate.

12 plus methotrexate and 458 to adalimumab plus methotrexate.

13 69 (44%) of 386 patients with adalimumab and methotrexate.

14 b pegol plus methotrexate or adalimumab plus methotrexate.

15 hotrexate is not superior to adalimumab plus methotrexate.

16 n to receive subcutaneous adalimumab or oral methotrexate.

17 l recovery after exposure to camptothecin or methotrexate.

18 y months, yet all of them went on to require methotrexate.

19 t decades with the introduction of high-dose methotrexate.

20 ted uveitis who were taking a stable dose of methotrexate.

21 y with glucocorticosteroids, thiopurines, or methotrexate.

22 gs: etanercept, ustekinumab, adalimumab, and methotrexate.

23 h tumor necrosis factor inhibitors than with methotrexate.

24 week 16, comparing adalimumab 0.8 mg/kg with methotrexate.

25 achieved clear or minimal PGA compared with methotrexate.

26 le in patients randomised to prednisone plus methotrexate (1.95 fold [95% CI 1.20-3.15] increase with

27 p=0.06 for tocilizumab plus methotrexate vs methotrexate, 1.14, 1.01-1.29, p=0.0356 for tocilizumab

28 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m(2) over 4 h.

29 Of 270 children taking methotrexate, 130 (48.1%) reported 1 or more AEs associa

30 .heme (17.6 kDa) and dihydrofolate reductase.methotrexate (19.4 kDa), minor changes were found in the

31 hosphamide 50 mg/day orally continuously and methotrexate 2.5 mg twice/day orally on days 1 and 2 of

32 He began treatment with oral methotrexate 20mg per week, which he tolerated well, and

33 trial to evaluate the efficacy of parenteral methotrexate (25 mg/wk) in 111 patients with corticoster

34 r panuveitis were randomized to receive oral methotrexate, 25 mg weekly, or oral mycophenolate mofeti

35 mostly caused by UC, than patients receiving methotrexate (26.7%; P = .03).

36 assigned (1:1:1) to receive four courses of methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2

37 randomly assigned to receive four courses of methotrexate 3.5 g/m(2) on day 1 plus cytarabine 2 g/m(2

38 rituximab 375 mg/m(2) 3 days before cycle 1; methotrexate 3.5 g/m(2) with leucovorin on weeks 1, 3, 5

39 to 7 cycles of chemotherapy with rituximab, methotrexate (3.5 g/m(2)), procarbazine, and vincristine

40 ts developed a serious treatment-related AE (methotrexate, 3; fumaric acid esters, 2; and adalimumab,

41 k 16 was achieved by 19 of 60 patients given methotrexate (31.7%) and 10 of 51 patients given placebo

42 (n=240) or investigator's choice (n=121) of methotrexate (40-60 mg/m(2) of body surface area), docet

43 Cyclosporine (66.4%), methotrexate (47.3%), azathioprine (30.9%), and anti-TNF

44 6 3-week cycles, or physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 30

45 nib monotherapy versus either adalimumab and methotrexate (-6 [-14 to 3]) or tofacitinib and methotre

46 otrexate (MTX) and its metabolites 7-hydroxy methotrexate (7-OH MTX) and 2,4-diamino-N(10)-methylpter

47 hotrexate (-6 [-14 to 3]) or tofacitinib and methotrexate (-8 [-16 to 1]).

48 s) and four courses of intravenous high-dose methotrexate 8000 mg/m(2) (every 10 days) and then two c

49 oclonal antibody tocilizumab with or without methotrexate (a conventional synthetic disease-modifying

50 33 (72%) of 46 administered prednisone plus methotrexate achieved a juvenile dermatomyositis PRINTO

51 nd ustekinumab are strongly recommended, and methotrexate, acitretin, infliximab, and apremilast are

52 Compared with methotrexate alone, the addition of anti-TNF drugs was s

53 ress through MTHFD1L knockdown or the use of methotrexate, an antifolate drug, sensitizes cancer cell

54 Twenty-seven patients were randomized to methotrexate and 16 to mycophenolate mofetil; 30 had acu

55 atients who received certolizumab pegol plus methotrexate and 386 [74%] of 523 patients who received

56 mly assigned; 457 to certolizumab pegol plus methotrexate and 458 to adalimumab plus methotrexate.

57 owed 5-year EFS rates of 79.6% for high-dose methotrexate and 75.2% for Capizzi methotrexate (P = .00

58 5]; p=0.532) between certolizumab pegol plus methotrexate and adalimumab plus methotrexate, respectiv

59 ovel roles for phosphatases in resistance to methotrexate and antimony, for ergosterol and phospholip

60 aric acid esters, 2; and adalimumab, 1), but methotrexate and biologic agents were taken for a mean d

61 rspective, an initial strategy of etanercept-methotrexate and biologics with similar cost and efficac

62 The treatment allowed dosing adjustments of methotrexate and capecitabine for pretreatment renal fun

63 t the CRP/IL-6/IL-1 axis, including low-dose methotrexate and colchicine, are being explored.

64 PG and treated with high-dose prednisolone, methotrexate and cyclosporine.

65 sone (hyper-CVAD) alternating with high-dose methotrexate and cytarabine every 21 days.

66 were enrolled and treated with high-doses of methotrexate and cytarabine, followed by R-HDS (cyclopho

67 d among eight patients who were treated with methotrexate and eight untreated age-matched control sub

68 e that were enriched via drug selection with methotrexate and five major antileishmanials (antimony,

69 orubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine plus a tyrosine ki

70 100 mg/m(2) on days 1 to 5, and a regimen of methotrexate and mercaptopurine.

71 rypanosoma brucei exposed to the antifolates methotrexate and raltitrexed.

72 e's susceptibly to the classical antifolates methotrexate and raltitrexed.

73 Methotrexate and the chemically similar drug aminopterin

74 The ICERs for first-line etanercept-methotrexate and triple therapy were $2.7 million per QA

75 When sustained remission was achieved, methotrexate (and placebo-methotrexate) was tapered and

76 59-2.51 for tocilizumab plus methotrexate vs methotrexate, and 1.86, 1.48-2.32 for tocilizumab vs met

77 3 (46%) of 376 patients with tofacitinib and methotrexate, and 169 (44%) of 386 patients with adalimu

78 ) of 376 patients receiving tofacitinib plus methotrexate, and 36 (9%) of 386 patients receiving adal

79 of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the t

80 k cycles of either classic cyclophosphamide, methotrexate, and fluorouracil (CMF; 600 mg/m(2) cycloph

81 sed chemotherapy with CMF (cyclophosphamide, methotrexate, and fluorouracil) as adjuvant chemotherapy

82 therapies (ie, intravenous cyclophosphamide, methotrexate, and infliximab) in these patients may be a

83 nd maintenance therapy comprising ATRA, oral methotrexate, and mercaptopurine.

84 included calcineurin inhibitor, short-course methotrexate, and methylprednisolone.

85 1.14, 1.01-1.29, p=0.0356 for tocilizumab vs methotrexate, and p=0.59 for tocilizumab plus methotrexa

86 nd salicylic acid along with oral retinoids, methotrexate, and tumor necrosis factor inhibitors as mo

87 citinib monotherapy; 376 had tofacitinib and methotrexate; and 386 had adalimumab and methotrexate).

88 imumab, etanercept, ustekinumab, infliximab, methotrexate, apremilast, and golimumab are recommended.

89 te initiation of tocilizumab with or without methotrexate are more effective, and with a similar safe

90 ive conditioning, unrelated donor (URD), and methotrexate are not known.

91 tocilizumab arm, and 48 (44%) of 108 in the methotrexate arm (relative risk [RR] 2.00, 95% CI 1.59-2

92 tocilizumab arm, and 83 (77%) of 108 in the methotrexate arm achieved sustained remission (RR 1.13,

93 86%) of 106 patients in the tocilizumab plus methotrexate arm achieved sustained remission on the ini

94 treatments; patients in the tocilizumab plus methotrexate arm switched to standard of care therapy (t

95 16%] of 106 patients in the tocilizumab plus methotrexate arm vs 19 [18%] of 103 in the tocilizumab a

96 e tocilizumab arm and 13 [12%] of 108 in the methotrexate arm), and no deaths occurred during the stu

97 umab plus methotrexate (the tocilizumab plus methotrexate arm), or tocilizumab plus placebo-methotrex

98 , 103 to the tocilizumab arm, and 108 to the methotrexate arm).

99 r methotrexate plus placebo-tocilizumab (the methotrexate arm).

100 ts to treatment (106 to the tocilizumab plus methotrexate arm, 103 to the tocilizumab arm, and 108 to

101 36%) of 106 patients in the tocilizumab plus methotrexate arm, 40 (39%) of 103 in the tocilizumab arm

102 86%) of 106 patients in the tocilizumab plus methotrexate arm, 91 (88%) of 103 in the tocilizumab arm

103 tocilizumab arm, and 37 (34%) of 108 in the methotrexate arm.

104 within-trial analysis found that etanercept-methotrexate as first-line therapy provided marginally m

105 ays -3, -2, -1 in addition to tacrolimus and methotrexate as GVHD prophylaxis.

106 Methotrexate-associated hepatic transaminase elevations

107 ous adalimumab (40 mg every other week) plus methotrexate at 194 centres in 25 countries.

108 cs were efficacious compared with placebo or methotrexate at 3-4 months.

109 ronic data capture system, to receive either methotrexate at a starting dose of 17.5 mg/week or place

110 permuted-block schedule stratified by use of methotrexate at baseline (0, >0 to <12.5 mg/week, or >/=

111 and 2015, prescribed any ISDs (cyclosporine, methotrexate, azathioprine, anti-TNF drugs, or others).

112 The antimetabolites, such as methotrexate, azathioprine, leflunomide, and mycophenola

113 domized controlled trials (N = 39) comparing methotrexate, azathioprine/6-mercaptopurine, infliximab,

114 e as consolidation therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 7

115 apy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy.

116 confirmed PCNSL after experiencing high-dose methotrexate-based chemotherapy failure who were not eli

117 High-dose methotrexate-based chemotherapy is standard for primary

118 High-dose methotrexate-based chemotherapy is the mainstay of treat

119 Induction consists of high-dose methotrexate-based polychemotherapy for most patients, w

120 The crystal structures of methotrexate binding to mt- and h-DHFR separately indica

121 months in patients assigned prednisone plus methotrexate but was not observable in the other two tre

122 r high-dose methotrexate (HD-MTX) or Capizzi methotrexate (C-MTX) during interim maintenance (IM) or

123 KCl or methotrexate can be injected directly into the foetal po

124 uced and/or rescheduled cyclophosphamide and methotrexate, capped vincristine, and used combination i

125 Use of methotrexate, ciclosporin, or cyclophosphamide as first

126 Etanercept and methotrexate combination is more effective than monother

127 n therapy was non-inferior to adalimumab and methotrexate combination therapy in the treatment of rhe

128 INTERPRETATION: Tofacitinib and methotrexate combination therapy was non-inferior to ada

129 tched to standard of care therapy (typically methotrexate combined with a tumour necrosis factor inhi

130 b 375 mg/m(2) (7 days before first high-dose methotrexate course and then every 10 days) and four cou

131 isease if they had been prescribed psoralen, methotrexate, cyclosporine, acitretin, adalimumab, etane

132 e first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (calle

133 pared with 23% (14-31) of those treated with methotrexate-cytarabine alone (hazard ratio 0.46, 95% CI

134 adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix

135 -0.74) and 30% (21-42) of those treated with methotrexate-cytarabine plus rituximab (0.61, 0.40-0.94)

136 y was more frequent in patients treated with methotrexate-cytarabine plus rituximab and thiotepa, but

137 m(2) on days -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiot

138 m(2) on days -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiot

139 High-dose methotrexate decreased both marrow and CNS recurrences.

140 Methotrexate did not affect protein phosphorylation in o

141 Therapy with systemic methotrexate did not suffice, as all the patients also r

142 tinib and methotrexate versus adalimumab and methotrexate (difference 2% [98.34% CI -6 to 11]) but no

143 %) of 386 patients receiving adalimumab plus methotrexate discontinued due to adverse events.

144 mg/m(2) with hand weakness, and intrathecal methotrexate dose >/=225 mg with dorsiflexion weakness.

145 cluding fluorouracil, carmustine, cisplatin, methotrexate, doxorubicin and paclitaxel.

146 included >/= two cycles of preoperative MAP (methotrexate, doxorubicin, and cisplatin), macroscopical

147 participants randomly assigned to high-dose methotrexate during interim maintenance 1 versus those r

148 armacological inhibition of folate action by methotrexate during neurulation induces NTDs by inhibiti

149 ed in relation to pharmacokinetic indices of methotrexate exposure and current chronic health conditi

150 , the impact of vitamin B12 availability and methotrexate exposure on Daphnia magna, which we hypothe

151 , 1.2 to 2.8) and >/= 4.3 g/m(2) intravenous methotrexate exposure was associated with global symptom

152 Etanercept-methotrexate first versus triple therapy first.

153 phamide/doxorubicin (AC) or cyclophosphamide/methotrexate/fluorouracil over single-agent capecitabine

154 and 75% for treatment with cyclophosphamide/methotrexate/fluorouracil, AC, and capecitabine, respect

155 uentially with cytarabine, asparaginase, and methotrexate for 6 months.

156 ecipients received CNI with mycophenolate or methotrexate for GVHD prophylaxis; 1245 patients receive

157 ase the risk of a second NMSC when used with methotrexate for RA.

158 recorded in three (3%) patients who received methotrexate for the full 52 week treatment period.

159 igh-dose methotrexate is superior to Capizzi methotrexate for the treatment of high-risk B-acute lymp

160 tinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis i

161 mpounds (BODIPY, colchicine, paclitaxel, and methotrexate) from membrane-enclosed depots is described

162 was longer in the afatinib group than in the methotrexate group (median 2.6 months [95% CI 2.0-2.7] f

163 compared with 12 (32%) of 37 patients in the methotrexate group (p=0.027).

164 ab 0.8 mg/kg group and 15 (41%) of 37 in the methotrexate group achieved clear or minimal PGA (p=0.08

165 inical remission at week 16 was 41.7% in the methotrexate group and 23.5% in the placebo group, for a

166 ndoscopic healing at week 16 were 35% in the methotrexate group and 25.5% in the placebo group--a dif

167 nse was achieved in 37 (41%) patients in the methotrexate group compared with three (10%) patients in

168 A higher proportion of patients in the methotrexate group had nausea and vomiting (21.7%) than

169 fatinib group vs none of 160 patients in the methotrexate group), diarrhoea (30 [9%] vs three [2%]),

170 mumab 0.4 mg/kg group; 21 [57%] of 37 in the methotrexate group).

171 atinib group vs 1.7 months [1.5-2.4] for the methotrexate group; hazard ratio [HR] 0.80 [95% CI 0.65-

172 weeks (methotrexate-methotrexate vs placebo-methotrexate groups).

173 1 versus those randomly assigned to Capizzi methotrexate had a 5-year event-free survival (EFS) of 8

174 old who received dexamethasone and high-dose methotrexate had a superior outcome compared with those

175 factorial design to receive either high-dose methotrexate (HD-MTX) or Capizzi methotrexate (C-MTX) du

176 rs, increased cumulative dose of intravenous methotrexate (ie, >4.3 g/m(2)) conferred increased risk

177 phamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytara

178 determining the transport of paclitaxel and methotrexate in brain tumour.

179 safety profile, compared with initiation of methotrexate in line with current standards.

180 iple therapy to be noninferior to etanercept-methotrexate in patients with active rheumatoid arthriti

181 intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-

182 52 week risk-benefit profile of subcutaneous methotrexate in patients with psoriasis.

183 52 week risk-benefit profile of subcutaneous methotrexate in patients with psoriasis.

184 s in patients with an inadequate response to methotrexate in this trial.

185 However, methotrexate induced clinical remission without steroids

186 6 or 7 times per week protected more against methotrexate-induced gastrointestinal AEs than did weekl

187 Methotrexate inhibited the catalytic activity of MNADK i

188 DK in hepatocytes and in livers in mice with methotrexate injection.

189 itor groups with minimisation to account for methotrexate intolerance using a web-based randomisation

190 ly assigned to groups (1:1) given placebo or methotrexate (intramuscularly or subcutaneously, 25 mg w

191 plemented with 0.5% sodium cholate) or given methotrexate intraperitoneally.

192 100 mg/m(2) orally on days 1-14; 40 mg/m(2) methotrexate intravenously on days 1 and 8; and 600 mg/m

193 Methotrexate is a first-line systemic agent for treating

194 Our results suggest that methotrexate is a promising treatment for myeloprolifera

195 Parenteral methotrexate is an effective treatment for patients with

196 Methotrexate is an immunomodulator with effects on helpe

197 se results show that certolizumab pegol plus methotrexate is not superior to adalimumab plus methotre

198 Methotrexate is one of the most commonly used systemic d

199 High-dose methotrexate is superior to Capizzi methotrexate for the

200 ed dosing schedule should be considered when methotrexate is used in this patient group.

201 er postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide

202 armacokinetic analysis showed that high-dose methotrexate maximum plasma concentration (estimate = 0;

203 Methotrexate may be added to glucocorticoids in patients

204 Adjunctive methotrexate may reduce cumulative glucocorticoid dosage

205 te treatment of all patients up to 52 weeks (methotrexate-methotrexate vs placebo-methotrexate groups

206 Methotrexate might be used in patients who relapse.

207 Methotrexate might bring the benefits of JAK/STAT pathwa

208 heumatic drug [DMARD]), versus initiation of methotrexate monotherapy in line with international guid

209 This study examined the impact of different methotrexate (MTX) and corticosteroid treatment strategi

210 f the therapeutically relevant drug molecule methotrexate (MTX) and its metabolites 7-hydroxy methotr

211 nvestigated high-dose intravenous (IV) pulse methotrexate (MTX) as a treatment for EF.

212 hand, pharmacological inhibition of DHFR by methotrexate (MTX) causes severe defects in oligodendroc

213 Methotrexate (MTX) is an anti-folate that inhibits de no

214 otherapies such as 5-Fluorouracil (5-FU) and methotrexate (MTX) leading to enhanced sensitivity in vi

215 f [F(7),P(34)]-NPY conjugates containing two methotrexate (MTX) molecules are presented.

216 ion immunochemotherapy (rituximab, high-dose methotrexate [MTX], vincristine, procarbazine) followed

217 mg/kg (n=38), adalimumab 0.4 mg/kg (n=39) or methotrexate (n=37).

218 we randomly assigned 120 patients to receive methotrexate (n=91) or placebo (n=29).

219 The risk was lower in patients who were methotrexate naive compared with traditional DMARD-exper

220 ears in the nonmethotrexate/nonbiologics and methotrexate/nonbiologics cohorts, respectively.

221 7, and T(H)22) mRNA expression compared with methotrexate nonresponders.

222 every other week starting at week 1, or oral methotrexate once weekly (0.1-0.4 mg/kg) for 16 weeks.

223 ared with non-biologic systemic therapies or methotrexate-only (etanercept: HR = 1.47, 95% CI = 0.95-

224 ification to receive certolizumab pegol plus methotrexate or adalimumab plus methotrexate.

225 tuximab vedotin versus physician's choice of methotrexate or bexarotene.

226 ne alone with that of prednisone plus either methotrexate or ciclosporin in children with new-onset j

227 idence comparing biologics with one another, methotrexate, or placebo.

228 py, oral tofacitinib (5 mg twice daily) plus methotrexate, or subcutaneous adalimumab (40 mg every ot

229 high-dose methotrexate and 75.2% for Capizzi methotrexate (P = .008).

230 xate, and 1.86, 1.48-2.32 for tocilizumab vs methotrexate, p<0.0001 for both comparisons).

231 5% CI 1.2-5.0] increase with prednisone plus methotrexate; p=0.012).

232 methotrexate versus Capizzi escalating-dose methotrexate plus pegaspargase during interim maintenanc

233 acebo-methotrexate (the tocilizumab arm), or methotrexate plus placebo-tocilizumab (the methotrexate

234 arthritis who was taking glucocorticoids and methotrexate presented to the emergency department in De

235 previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or

236 previous thiopurines, previous infliximab or methotrexate, previous surgery, duration of disease, or

237 8.1%) reported 1 or more AEs associated with methotrexate, primarily gastrointestinal (67 [24.8%]).

238 ring showed the superiority of the high-dose methotrexate regimens, which exceeded the predefined bou

239 e syndrome, peripheral neuropathy, high-dose methotrexate-related nephrotoxicity, sinusoidal obstruct

240 seizures, depressed level of consciousness, methotrexate-related stroke-like syndrome, peripheral ne

241 of 523 patients who received adalimumab plus methotrexate reported treatment-emergent adverse events.

242 pegol plus methotrexate and adalimumab plus methotrexate, respectively.

243 .001) compared with late downregulation for methotrexate responders (week 2, -0.44 [0.68], P = .64;

244 Methotrexate responders experienced significant downregu

245 ion at study completion among adalimumab and methotrexate responders suggest a disease-driven instead

246 L22 (P = .006) mRNA comparing adalimumab and methotrexate responders.

247 A combination of infliximab with methotrexate results in greater efficacy than infliximab

248 Combination studies with methotrexate revealed that compound 13 (3-hydroxy-6-meth

249 io [RR], 1.09 [95% CI, 0.62-1.93]; P = .99), methotrexate (RR, 0.98 [95% CI, 0.78-1.23]; P = .83), cy

250 eks after a loading dose) or low-dosage oral methotrexate sodium (7.5-25 mg/wk).

251 riasis to aid in determining eligibility for methotrexate sodium (MTX) therapy, monitor for the devel

252 Methotrexate sodium (OR, 0.60; 95% CI, 0.29-1.22), merca

253 In mice given injections of methotrexate, supplementation of a diet with nicotinamid

254 tacrolimus/sirolimus (Tac/Sir) vs tacrolimus/methotrexate (Tac/Mtx) as graft-versus-host disease (GVH

255 d the treatment of primary CNS lymphoma with methotrexate, temozolomide (TMZ), and rituximab, followe

256 ontinuation of the drug was more likely with methotrexate than tumor necrosis factor inhibitors, but

257 a ratiometric fluorescent sensor protein for methotrexate that exhibits large dynamic ranges both in

258 thotrexate arm), or tocilizumab plus placebo-methotrexate (the tocilizumab arm), or methotrexate plus

259 d patients (1:1:1) to start tocilizumab plus methotrexate (the tocilizumab plus methotrexate arm), or

260 With the exception of methotrexate, the use of medications for IBD should not

261 nts with active rheumatoid arthritis despite methotrexate therapy are lacking.

262 der with active rheumatoid arthritis despite methotrexate therapy.

263 patients with psoriasis receiving long-term methotrexate therapy.

264 with active RA despite at least 12 weeks of methotrexate therapy.

265 Exposure to methotrexate, thiopurines, anti-TNFs, sulfasalazine, hyd

266 ulture caused quiescence and protection from methotrexate toxicity in Mer(high) ALL cell lines, which

267 Tubules accumulate dextran and methotrexate transport cargoes, and express kidney injur

268 Both folate and methotrexate transport were inhibited by classical antif

269 Methotrexate-treated cancer survivors had significantly

270 of afatinib-treated patients and 18 (11%) of methotrexate-treated patients.

271 to 22.5 mg/week was allowed after 8 weeks of methotrexate treatment if patients had not achieved at l

272 placebo for the first 16 weeks, followed by methotrexate treatment of all patients up to 52 weeks (m

273 rrently moderate to severe disease, and were methotrexate treatment-naive.

274 isk of NMSC increased with 1 year or more of methotrexate use (HR, 1.24; 95% CI, 1.04-1.48).

275 Methotrexate use is associated with an increased risk of

276 Among patients with RA, methotrexate used in conjunction with other medications

277 inferiority was declared for tofacitinib and methotrexate versus adalimumab and methotrexate (differe

278 one (28 days) during induction and high-dose methotrexate versus Capizzi escalating-dose methotrexate

279 termine the cost-effectiveness of etanercept-methotrexate versus triple therapy as a first-line strat

280 les of gemcitabine plus cisplatin, high-dose methotrexate, vinblastine, doxorubicin, and cisplatin [h

281 5% CI 1.00-1.29, p=0.06 for tocilizumab plus methotrexate vs methotrexate, 1.14, 1.01-1.29, p=0.0356

282 2.00, 95% CI 1.59-2.51 for tocilizumab plus methotrexate vs methotrexate, and 1.86, 1.48-2.32 for to

283 ethotrexate, and p=0.59 for tocilizumab plus methotrexate vs tocilizumab).

284 Higher plasma methotrexate was also associated with higher functional

285 Higher plasma concentration of methotrexate was associated with a poorer executive func

286 A higher plasma concentration of methotrexate was associated with executive dysfunction a

287 Subcutaneous methotrexate was generally well tolerated; no patients d

288 nt with prednisone and either ciclosporin or methotrexate was more effective than prednisone alone.

289 In a randomized controlled trial, parenteral methotrexate was not superior to placebo for induction o

290 Methotrexate was started at 10 mg per week orally and in

291 Methotrexate was used by 270 patients (69.2%), biologic

292 sion was achieved, methotrexate (and placebo-methotrexate) was tapered and stopped, then tocilizumab

293 atients were randomized to either 25 mg oral methotrexate weekly or 1 g mycophenolate mofetil twice d

294 steroid-sparing control of inflammation with methotrexate were 2.5 times (95% CI: 0.6, 9.8; P = .20)

295 The transport kinetics of folate and methotrexate were further characterized in whole cells.

296 Patients who were taking a stable dose of methotrexate were randomly assigned in a 2:1 ratio to re

297 Anti-TNF treatment, as well as metformin and methotrexate, which are associated with decreased stroke

298 ly by derepression of the FAS promoter using methotrexate, which we showed previously has activity as

299 erapy comprising cisplatin, doxorubicin, and methotrexate with intercalated surgery is the standard o

300 nalysis suggested that first-line etanercept-methotrexate would result in 0.15 additional lifetime QA